Abstract
Tirbanibulin 1% ointment was approved for actinic keratosis (AK) of face or scalp based on two Phase 3 trials. Pooled rates of complete (100%) clearance (CC) and partial (≥75%) clearance (PC) in these trials were reported for Day (D) 57 of treatment, being 49% and 72% respectively. We present post-hoc efficacy and safety analyses evaluating earlier time points.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
